Immix Biopharma (NASDAQ:IMMX) Stock Price Expected to Rise, Mizuho Analyst Says

Immix Biopharma (NASDAQ:IMMX) had its price objective boosted by equities research analysts at Mizuho from $14.00 to $15.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s price objective would suggest a potential upside of 64.65% from the company’s previous close.

A number of other brokerages have also recently issued reports on IMMX. Wall Street Zen cut Immix Biopharma from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a report on Thursday, January 22nd. Citizens Jmp reissued a “market outperform” rating and issued a $23.00 price target on shares of Immix Biopharma in a report on Friday, March 27th. HC Wainwright raised their price objective on shares of Immix Biopharma from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, March 27th. Finally, Morgan Stanley started coverage on shares of Immix Biopharma in a research note on Wednesday, March 25th. They set an “overweight” rating and a $20.00 price objective for the company. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $18.25.

Immix Biopharma Trading Up 6.2%

Immix Biopharma stock opened at $9.11 on Monday. The firm has a 50 day simple moving average of $7.94 and a 200 day simple moving average of $5.38. Immix Biopharma has a 1-year low of $1.34 and a 1-year high of $11.61. The firm has a market capitalization of $482.56 million, a price-to-earnings ratio of -10.24 and a beta of 0.25.

Immix Biopharma (NASDAQ:IMMX) last posted its earnings results on Wednesday, March 25th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.12). On average, equities research analysts forecast that Immix Biopharma will post -0.87 EPS for the current year.

Institutional Investors Weigh In On Immix Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of IMMX. Velan Capital Investment Management LP bought a new stake in Immix Biopharma during the second quarter valued at approximately $52,000. Vanguard Group Inc. increased its holdings in shares of Immix Biopharma by 4.5% in the 3rd quarter. Vanguard Group Inc. now owns 730,162 shares of the company’s stock worth $1,526,000 after buying an additional 31,625 shares during the last quarter. Tocqueville Asset Management L.P. increased its holdings in shares of Immix Biopharma by 37.4% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock worth $84,000 after buying an additional 10,950 shares during the last quarter. Imprint Wealth LLC purchased a new stake in shares of Immix Biopharma during the 3rd quarter valued at $141,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Immix Biopharma during the 3rd quarter valued at $188,000. 11.26% of the stock is owned by hedge funds and other institutional investors.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.